9.34
+0.97%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Q32 Bio
From its filings with the US Securities and Exchange Commission
Q32 Bio is based in Waltham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker QTTB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $53.7m and net income of $29.8m. At that date it held total assets of $61.8m and shareholders' equity of $42.0m.
We are a clinical stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with alopecia areata (“AA”) and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Bempikibart (ADX-914), our most advanced product candidate, is a fully human anti–interleukin-7 receptor alpha (“IL-7Rα”), antagonist monoclonal antibody designed to re-regulate adaptive immune function by potently blocking signaling mediated by interleukin-7 (“IL-7”), and thymic stromal lymphopoietin (“TSLP”). We have completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL-AA Part A, for the treatment of AA, and SIGNAL-AD, for the treatment of atopic dermatitis (“AD”).
In December 2024, we announced topline results from both of these trials, as well as our intention to advance bempikibart for the treatment of AA. In April 2025, we announced dosing of the first patients in both the Part A open-label extension and Part B of the SIGNAL-AA Phase 2a clinical trial and in October 2025, we announced completion of enrollment in SIGNAL-AA Part B. Bempikibart is being evaluated for the treatment of AA in the ongoing Part B of the SIGNAL-AA Phase 2a clinical trial. Enrollment has been completed in the Part B portion of the clinical trial, with 33 patients enrolled, and dosing remains ongoing. We expect to report 36-week topline data from the SIGNAL-AA Part B trial in mid-2026.
Quoted from its 10-K, filed 10 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Mar 2018
- Employees
- 24
- Website
- homologymedicines.com ↗
- Head office
- 830 WINTER STREET, WALTHAM, MA, 02451
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Mark IwickiIndependent Chairman of the Board$414,531
- Mr. Lee KalowskiPresident, Chief Financial Officer$2.9m
- Ms. Jodie MorrisonChief Executive Officer, Director, since 2024$6.0m
- Dr. Shelia VioletteChief Scientific Officer, President of Research$716,221
- Dr. Jason CampagnaChief Medical Officer$1.5m
- Dr. Adrien SiposInterim Chief Medical Officer
- Dr. Arthur TzianabosDirector$216,034
- Dr. David GrayzelIndependent Director$199,099
- Ms. Kathleen LaporteIndependent Director$223,662
- Dr. Bill LundbergIndependent Director$217,530
- Dr. Isaac MankeIndependent Director$199,865
- Ms. Mary ThistleIndependent Director$222,631
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 61
- Social
- 77
- Governance
- 38
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HMI-102 is a gene therapy for the treatment of phenylketonuria.
- The company employs 205 full-time employees in the biotechnology sector.
- 15 adeno-associated virus vectors enable precise gene correction methods.
Weaknesses
- The company has only 24 employees listed in the data.
- Bedford is the headquarters city for Homology Medicines, Inc.
- The listing date was 28 March 2018 on the market.
Opportunities
- The pipeline targets rare diseases at the genetic level globally.
- Gene therapy approaches focus on adults with monogenic diseases.
- Single intravenous injections target liver, CNS, and other tissues.
Threats
- Monogenic diseases in the liver require complex genetic treatments.
- Central nervous system treatments face significant biological delivery challenges.
- Bone marrow and lung therapies involve high development risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.